GlassScriptPhysician profile
Johnny Espinoza
NPI 1447819321
$722.71
in general payments reported to CMS, 2019-2025
14 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.92 · 2021: $98.63 · 2023: $159 · 2024: $171 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $221.91 | 2024-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $121.81 | 2023 | |
| Amgen INC. | $90.96 | 2025 | Tavneos |
| Nxstage Medical, INC. | $61.15 | 2025 | Nxstage System One, Liberty Select Cycler |
| Cormedix INC. | $35.71 | 2024 | Defencath |
| Vifor Pharma, INC. | $33.83 | 2023-2024 | Veltassa, Korsuva |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.88 | 2019-2021 | |
| Kyowa Kirin, INC. | $28.97 | 2021 | |
| Aurinia Pharma U.S., INC. | $23.57 | 2023 | |
| Baxter Healthcare | $16.22 | 2024 | Renal - Acute |
| Alexion Pharmaceuticals, INC. | $15.64 | 2021 | |
| Pfizer INC. | $14.27 | 2021 | |
| Lundbeck LLC | $13.86 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.